Growth hormone deficiency
Conditions
Interventions
None listed
Sponsors
Pfizer Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male and female patients of any age must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1 Prescription of Genotropin daily hGH for GHD per local diagnostic guidelines, prescription of other daily hGH treatments for GHD per local diagnostic guidelines, or prescription of Ngenla long-acting hGH per local diagnostic guidelines. 2 Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed and agree to all pertinent aspects of the study. Assent will also be sought from children of applicable age in line with national guidance. In all cases, the treating physician responsible for enrolling the patient into the registry will assess the appropriateness of gaining assent from a patient (or a legally acceptable representative) at their discretion during routine clinical care. 3 Germany only: The treating clinician has confirmed that the patient receiving a prescription treatment for GHD is eligible according to the summary of product characteristics (SmPC) indications and contraindications.
Exclusion criteria
Exclusion criteria: 1. Participation in any interventional clinical trials at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate incidence rates (IRs) of safety events of interest among patients on Genotropin, other daily hGH treatments, and Ngenla. To describe and compare effectiveness of Genotropin, other daily hGH treatments, and Ngenla. | — |
Countries
Japan,Asia(except Japan),North America,Australia,Europe
Contacts
Public ContactMisa Arata
IQVIA Services Japan K.K. Real-World Evidence Services
Outcome results
None listed